The agenda for the 3 September 2014 Transparency Commission is now available. The Commission will consider the following new medicines and new uses for existing medicines:

• Misoprosol (Misodel) - new medicine
• Paclitaxel (nanoparticle albumin bound) (Abraxane) - new indication
• Anakinra (Kineret) - new medicine
• Panitumumab (Vectibix) - new indication (appeal hearing)

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2014-08/odj_internet_ct_03092014.pdf [French]